Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the licensing agreement, SunRock will concentrate on the clinical development of SRB19 using Debiopharm’s Multilink technology to create an improved HER3-EGFR bispecific antibody-drug conjugate for treating head and neck cancer.
Lead Product(s): SRB19
Therapeutic Area: Oncology Product Name: SRB19
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2024
Details:
Under the agreement, Debiopharm will boost its ADC oncology pipeline through SunRock’s antibody portfolio, including SRB21, an anti-HER3-HER2 bispecific, integrating Debiopharm’s Multilink™ & AbYlink™ technologies to create innovative antibody drug conjugates (ADCs).
Lead Product(s): SRB21
Therapeutic Area: Oncology Product Name: SRB21
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 21, 2023
Details:
Under the agreement, Ellipses has been granted global rights to develop and commercialise EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound.
Lead Product(s): SRB22
Therapeutic Area: Oncology Product Name: EP0017
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ellipses Pharma Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 25, 2022